FDA warns another homeopathic company; Bosch expands in India; Alembic licenses drug scoring technology;

> The FDA has sent a warning letter to an Iowa company saying the claims attached to its homeopathic drugs for such things as boosting male sexual energy and treating arthritis qualify them as prescription medications. FDA warning letter

> Bosch Packaging Technology India has opened a new €5 million ($6.2 million) plant in Verna, Goa, India, to make fill-and-seal packaging equipment for the pharmaceutical industry, as well as packaging machines for food and other industries. Story 

> Indian generics maker Alembic has a licensing agreement with Accu-Break to use its drug scoring technology on its products, starting with its generic warfarin. Story 

> India's manufacturing expertise is being touted as one reason its contract research and manufacturing sector is now producing about $8.2 billion annually. Story 

> Bail has been extended by a Pakistan court for Ali Musa Gilani, son of former Prime Minister Syed Yousuf Raza Gilani, who has been implicated in a case in which ephedrine was diverted to street drugs. Story 

> Pfizer ($PFE) has officially filed for its initial public offering to spin off its animal health unit. Story 

> Investor Carl Icahn says Forest Laboratories, while under a consent decree, has gotten its second FDA warning letter for aggressive marketing tactics. Story 

And Finally... A Taro Pharmaceuticals investor claims that FDA manufacturing oversight drove many ointment and cream producers away, laying the groundwork for the spike in prices for dermatology drugs patients are facing. Story

Suggested Articles

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.